Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

Husain Nazik Elmalaika; Hassan Abdallah Tang; Elmadhoun Wadie M.; Ahmed Mohamed H.

首页> 外文期刊>Expert opinion on drug safety >Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

【24h】

Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

机译：评估Liptruzet（依泽替米贝和阿托伐他汀）的安全性：除了降低低密度脂蛋白胆固醇的作用外，还有哪些潜在益处？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: The combination of ezetimibe and atorvastatin (Liptruzet-referred to in this article as eze/ator), has recently been approved by the FDA for reducing low-density lipoprotein cholesterol (LDL-c) in patients with primary or mixed hyperlipidemia as in case of homozygous familial hypercholesterolemia. It helps block intestinal absorption of cholesterol and it inhibits the production of cholesterol in the liver.

机译：简介：依泽替米贝和阿托伐他汀（Liptruzet在本文中称为eze / ator）的组合，最近已被FDA批准用于降低原发性或混合性高脂血症患者的低密度脂蛋白胆固醇（LDL-c）。纯合子家族性高胆固醇血症。它有助于阻止肠道对胆固醇的吸收，并抑制肝脏中胆固醇的产生。

著录项

来源
《Expert opinion on drug safety》 |2015年第9期|共11页
作者
Husain Nazik Elmalaika; Hassan Abdallah Tang; Elmadhoun Wadie M.; Ahmed Mohamed H.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药品;
关键词
atorvastatin; coronary heart disease; ezetimibe; fatty liver; hyperlipidemia; insulin resistance; Liptruzet;

机译：阿托伐他汀;冠心病;依泽替米贝;脂肪肝;高脂血症;胰岛素抵抗;Liptruzet;

相似文献

外文文献
中文文献
专利

1. Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? [J] . Husain Nazik Elmalaika, Hassan Abdallah Tang, Elmadhoun Wadie M., Expert opinion on drug safety . 2015,第9期

机译：评估Liptruzet（依泽替米贝和阿托伐他汀）的安全性：除了降低低密度脂蛋白胆固醇的作用外，还有哪些潜在益处？
2. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. [J] . Cruz Fernandez JM, Bedarida GV, Adgey J, International journal of clinical practice . 2005,第6期

机译：依泽替米贝联合正在进行的阿托伐他汀治疗在高胆固醇血症和冠心病患者中实现低密度脂蛋白目标的功效和安全性。
3. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) anal [J] . Giraldez RR, Giugliano RP, Mohanavelu S, Journal of the American College of Cardiology . 2008,第11期

机译：基线低密度脂蛋白胆固醇是强化降脂治疗益处的重要预测指标：PROVE IT-TIMI 22（普伐他汀或阿托伐他汀评估和心肌梗塞的感染性血栓溶解治疗）22
4. In vitro evaluation of newly developed adsorbent for selective removal of Low-density lipoprotein [C] . Rui zhong, Hong Wang, Ye Cao, World biomaterials congress . 2012

机译：新开发的选择性去除低密度脂蛋白吸附剂的体外评估
5. Evaluating Mobility and Safety Benefits of Freeway Service Patrols: A Case Study of Florida's Road Rangers [D] . Salum, Jimoku H. 2019

机译：高速公路服务巡逻的评价流动性和安全益处 - 佛罗里达路游侠的案例研究
6. A multicentre open-label observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population [O] . Frederick Raal, Colin Schamroth, Jai Patel, 2007

机译：一项多中心开放性观察性本地研究以评估南非人群日常实践中规定的依泽替米贝的低密度脂蛋白胆固醇降低作用
7. Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy A PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) Analysis [O] . Giraldez Roberto R., Giugliano Robert P., Mohanavelu Satishkumar, 2008

机译：基线低密度脂蛋白胆固醇是降血脂强化治疗益处的重要预测指标PROVE IT–TIMI 22（普伐他汀或阿托伐他汀评估及感染治疗–心肌梗死中的血栓溶解）分析

Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?

摘要

著录项

相似文献

相关主题

期刊订阅